Syschem (India) Ltd
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.
- Market Cap ₹ 211 Cr.
- Current Price ₹ 48.6
- High / Low ₹ 62.0 / 35.3
- Stock P/E 46.7
- Book Value ₹ 21.8
- Dividend Yield 0.00 %
- ROCE 1.47 %
- ROE 0.62 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company's median sales growth is 40.0% of last 10 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 | 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 199 | 332 | 410 | |
| 14 | 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 192 | 328 | 401 | |
| Operating Profit | 4 | -3 | -1 | 0 | 3 | 4 | -0 | -5 | 1 | 9 | 7 | 4 | 9 |
| OPM % | 22% | -23% | -24% | 0% | 5% | 4% | -0% | -7% | 1% | 8% | 4% | 1% | 2% |
| 1 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 1 | -5 | -3 | -2 | 1 | 2 | -2 | -7 | -2 | 6 | 4 | 1 | 6 |
| Tax % | 21% | -26% | -27% | -30% | 43% | 50% | -16% | -24% | -22% | 27% | 33% | 54% | |
| 1 | -4 | -2 | -1 | 0 | 1 | -2 | -6 | -2 | 5 | 3 | 0 | 5 | |
| EPS in Rs | 0.30 | -1.94 | -1.13 | -0.75 | 0.17 | 0.32 | -0.79 | -2.07 | -0.59 | 1.13 | 0.69 | 0.11 | 1.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 34% |
| 3 Years: | 78% |
| TTM: | 62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 18% |
| 3 Years: | 31% |
| TTM: | 955% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 49% |
| 3 Years: | 8% |
| 1 Year: | 2% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | 6% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 40 | 44 | 44 |
| Reserves | -2 | -6 | -8 | -10 | -8 | -8 | -10 | -15 | -16 | -10 | 17 | 48 | 51 |
| 32 | 28 | 27 | 22 | 20 | 16 | 17 | 16 | 2 | 2 | 0 | 0 | 0 | |
| 9 | 13 | 12 | 16 | 29 | 35 | 36 | 55 | 51 | 69 | 107 | 126 | 87 | |
| Total Liabilities | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 182 |
| 36 | 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 31 | 53 | 52 | |
| CWIP | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 0 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 129 | 164 | 119 | |
| Total Assets | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 182 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 1 | 0 | 6 | 0 | -2 | 3 | 4 | 1 | -8 | -26 | -10 | |
| -3 | 0 | 0 | 0 | 0 | 2 | -4 | -4 | -1 | -2 | -6 | -22 | |
| -1 | -2 | -1 | -7 | -0 | -0 | -0 | -0 | -0 | 11 | 32 | 34 | |
| Net Cash Flow | 0 | -1 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 1 | -0 | 2 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 143 | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 | 126 | 99 |
| Inventory Days | 280 | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 | 107 | 81 |
| Days Payable | 183 | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 | 198 | 143 |
| Cash Conversion Cycle | 240 | 124 | 271 | -119 | -24 | -7 | -19 | 9 | -14 | 38 | 34 | 36 |
| Working Capital Days | -12 | -139 | -564 | -319 | -50 | -20 | -36 | -1 | -15 | 48 | 54 | 39 |
| ROCE % | 8% | -11% | -8% | -6% | 3% | 7% | -8% | -29% | -12% | 38% | 11% | 1% |
Documents
Announcements
- As Per Regulation 47 Read With Schedule III Of SEBI (LODR), 2015 Newspaper Publication For The Quarter 2 Results. 11 Nov
- Results For The Quarter Ending 30Th September, 2025 10 Nov
-
Board Meeting Outcome for Results_Q2 September, 2025: Outcome Of Board Meeting
10 Nov - Approved unaudited financial results for quarter/half-year ended 30 Sep 2025; limited review report recorded.
-
Board Meeting Intimation for Intimation Of The Board Meeting
24 Oct - Board meeting 10 Nov 2025, 11:00 AM to approve Q2/H1 unaudited results; trading window closed.
-
Compliance: Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI( LODR), 2015
23 Oct - No fund-raise or deviations for quarter ended 30 Sep 2025; Regulation 32 not applicable.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1]
API/ Intermediates:
a) Amoxycillin Tri Hydrate
b) Ampicillin Tri Hydrate
c) Cloxacillin Sodium
d) Dicloxacillin Sodium
e) Flucloxacillin Sodium (For export only)
f) Cephalexin
g) Cefixime
h) Cefadroxil
i) Distillation of Specialty Solvents –
DMF, Acetonitrile, Ethyl Acetate and THF